Trial Profile

A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CHP-MAGE-A4 (Primary)
Indications Cancer; Malignant melanoma
Focus Adverse reactions

Most Recent Events

09 Oct 2013 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
07 Jan 2012 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan.
16 Sep 2011 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com